Instructions for Alflutop ampoules
Release Form:
Injection solution
Description:
The injection solution is transparent, colorless or slightly brown-yellow, or slightly yellow.
1 ml
bioactive concentration of small marine fish* 0.1 ml
Sprattus sprattus sprattus, the family of herring (Clupeidae); Merlang, Odontogadus merlangus euxinus, Gadidae; Alosa tanaica nordmanni, the family of herring (Clupeidae); Engraulis encrassicholus ponticus, the Anchous family (Engraulidae). Bio-active concentrate is obtained by extraction with subsequent deproteinization and delidification.
Auxiliary substances: phenol - no more than 0.005 g, water d/i - up to 1 ml.
ATX codes
M09AX Other drugs for the treatment of diseases of the bone and muscle system
Pharmacological groups / Group membership:
Stimulus for recovery of natural tissue
Active substance:
bioactive concentrate of fine marine fish
Pharmacy Group:
Tissue recovery natural origin stimulator
Retention Terms:
The drug should be stored in a place not accessible to children, protected from light at temperatures from 15° to 25° C.
Shelf life
Shelf life - 3 years. Do not use an expired drug.
Pharmaceuticals:
Alflutope is a chondrotrek, the active component of which is a bioactive concentrate made of fine marine fish. Concentrate contains mulco-polysaccharides (chondroitin sulfate), amino acids, peptides, sodium ions, potassium, calcium, magnesium, iron, copper and zinc.
Alflutop prevents the destruction of the macromolecular structures of normal tissues, stimulates the recovery processes in the interstitial tissue and the tissue of the joint cartilage, which explains its analgesic effect.
Anti-inflammatory action and tissue regeneration are based on the suppression of hyaluronidase activity and the normalization of hyaluronic acid biosynthesis.
Both of these effects are synergistic and trigger the activation of remediation processes in tissues, in particular the restoration of cartilage structure.
Testimonials:
primary and secondary osteoartrosis of various localization (coxartrosis, gonartrosis, arthrosis of small joints);
spondilesis;
osteochondrosis.
Method of application, course and dosage:
For polyosteoarthrosis and osteochondrosis, the drug is injected deep into/m:
For 1 ml/day, the treatment rate is 20 injections (1 injection per day for 20 days), or
2 ml per day, the treatment is 10 injections (1 injection per day for 20 days).
In the case of major joint damage, the drug is administered intravenously by 1-2 ml per joint with a interval of 3-4 days. Treatment course - 5-6 injections in each joint.
A combination of in/m and in-house introduction is possible.
The course of treatment should be repeated in 6 months after the doctor's consultation.
Overdose:
Doso-dependent unwanted drug reactions increase during overdose.
Drug Interaction:
To date, the drug interaction of Alflutop has not been detected.
Use in pregnancy and breastfeeding
The drug is contraindicated to use during pregnancy and lactation (breastfeeding).
Side Action:
Side effects are grouped according to the WHO classification of the frequency of unwanted reactions: very often (≥1/10), often (≥1/100 to <1/10), infrequently (≥1/1000 to <1/100), rarely (≥1/1000 to < 1/1000), very rarely (<1/10000), frequency unknown (frequency cannot be determined from available data).
Rare: heated dermatitis, redness of the skin, burning sensation at the place of injection of the drug, short-term myalgia.
Very rarely: anaphylactic reactions.
Frequency unknown: A transient enhancement of pain syndrome (in the case of intravenous introduction).
Contraindications to use:
increased sensitivity to drug components;
pregnancy;
lactation period (breastfeeding);
Age up to 18 years (due to lack of clinical data in this category of patients).
Special Instructions:
In case of individual non-tolerability of seafood (marine fish) the risk of development of allergic reactions increases.
Impact on the ability to drive vehicles and mechanisms
The use of the drug has no effect on the ability to carry out potentially dangerous activities requiring increased attention and speed of psychomotor reactions (driving, working with moving mechanisms, operation of the manager and operator).
Terms of implementation:
The drug is released according to the prescription.
Application of children:
Contravenous to the age of 18 (due to lack of clinical data in this category of patients).
Nozology (ICD codes)
M15
Polyarthrosis
M16
Coxarthrosis [hip arthrosis]
M17
Gunartrose [knee joint arthrosis]
M19.9
Arthrosis unspecified
M42
Osteochondrosis of the spine
M47
Spondiles
